{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T18:50:09Z","timestamp":1793213409254,"version":"4.5.0"},"reference-count":31,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"vor","delay-in-days":730,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100002855","name":"Ministry of Science and Technology of the People&apos;s Republic of China","doi-asserted-by":"publisher","award":["2019FY101101"],"award-info":[{"award-number":["2019FY101101"]}],"id":[{"id":"10.13039\/501100002855","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jtcvsonline.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Thoracic and Cardiovascular Surgery"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1016\/j.jtcvs.2023.12.030","type":"journal-article","created":{"date-parts":[[2024,1,19]],"date-time":"2024-01-19T11:54:45Z","timestamp":1705665285000},"page":"417-428.e3","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":64,"title":["Neoadjuvant chemotherapy combined with immunotherapy versus neoadjuvant chemoradiotherapy in patients with locally advanced esophageal squamous cell carcinoma"],"prefix":"10.1016","volume":"168","author":[{"given":"Yong-kui","family":"Yu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fan-Yu","family":"Meng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiu-feng","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xian-kai","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao-miao","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Can-jun","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hou-nai","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui-xiang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenqun","family":"Xing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.jtcvs.2023.12.030_bib1","first-page":"209","article-title":"Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"issue":"2","key":"10.1016\/j.jtcvs.2023.12.030_bib2","first-page":"115","article-title":"Cancer statistics in China, 2015","volume":"66","author":"Chen","year":"2016","journal-title":"CA Cancer J Clin"},{"issue":"7","key":"10.1016\/j.jtcvs.2023.12.030_bib3","doi-asserted-by":"crossref","first-page":"855","DOI":"10.6004\/jnccn.2019.0033","article-title":"Esophageal and esophagogastric junction cancers, version 2.2019, NCCN clinical practice guidelines in oncology","volume":"17","author":"Ajani","year":"2019","journal-title":"J Natl Compr Canc Netw"},{"issue":"5","key":"10.1016\/j.jtcvs.2023.12.030_bib4","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1097\/SLA.0000000000004329","article-title":"Neoadjuvant chemoradiotherapy using cisplatin and 5-fluorouracil (PF) versus carboplatin and paclitaxel (CROSS regimen) for esophageal squamous cell carcinoma (ESCC): a propensity score-matched study","volume":"272","author":"Wong","year":"2020","journal-title":"Ann Surg"},{"key":"10.1016\/j.jtcvs.2023.12.030_bib5","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.ejca.2020.08.002","article-title":"Recurrence patterns after neoadjuvant chemoradiotherapy compared with surgery alone in oesophageal squamous cell carcinoma: results from the multicenter phase III trial NEOCRTEC5010","volume":"138","author":"Liu","year":"2020","journal-title":"Eur J Cancer"},{"issue":"1","key":"10.1016\/j.jtcvs.2023.12.030_bib6","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1245\/s10434-011-2049-9","article-title":"A randomized trial comparing postoperative adjuvant chemotherapy with cisplatin and 5-fluorouracil versus preoperative chemotherapy for localized advanced squamous cell carcinoma of the thoracic esophagus (JCOG9907)","volume":"19","author":"Ando","year":"2012","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.jtcvs.2023.12.030_bib7","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2020.100422","article-title":"Clinical evidence for association of neoadjuvant chemotherapy or chemoradiotherapy with efficacy and safety in patients with resectable esophageal carcinoma (NewEC study)","volume":"24","author":"Zhou","year":"2020","journal-title":"EClinicalMedicine"},{"issue":"17","key":"10.1016\/j.jtcvs.2023.12.030_bib8","doi-asserted-by":"crossref","first-page":"2257","DOI":"10.2217\/fon-2021-0021","article-title":"Survival and complications after neoadjuvant chemotherapy or chemoradiotherapy for esophageal cancer: a meta-analysis","volume":"17","author":"Han","year":"2021","journal-title":"Future Oncol"},{"issue":"5","key":"10.1016\/j.jtcvs.2023.12.030_bib9","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1001\/jamasurg.2021.0133","article-title":"Morbidity and mortality of patients who underwent minimally invasive esophagectomy after neoadjuvant chemoradiotherapy vs neoadjuvant chemotherapy for locally advanced esophageal squamous cell carcinoma: a randomized clinical trial","volume":"156","author":"Wang","year":"2021","journal-title":"JAMA Surg"},{"issue":"4","key":"10.1016\/j.jtcvs.2023.12.030_bib10","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1007\/s00432-021-03659-7","article-title":"Neoadjuvant chemoradiotherapy versus neoadjuvant chemotherapy for the treatment of esophageal squamous cell carcinoma: a propensity score-matched study from the National Cancer Center in China","volume":"148","author":"Zhang","year":"2022","journal-title":"J Cancer Res Clin Oncol"},{"issue":"10","key":"10.1016\/j.jtcvs.2023.12.030_bib11","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1001\/jama.2021.12836","article-title":"Effect of camrelizumab vs placebo added to chemotherapy on survival and progression-free survival in patients with advanced or metastatic esophageal squamous cell carcinoma: the ESCORT-1st randomized clinical trial","volume":"326","author":"Luo","year":"2021","journal-title":"JAMA"},{"issue":"5","key":"10.1016\/j.jtcvs.2023.12.030_bib12","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1056\/NEJMoa2111380","article-title":"Nivolumab combination therapy in advanced esophageal squamous-cell carcinoma","volume":"386","author":"Doki","year":"2022","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.jtcvs.2023.12.030_bib13","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1002\/cac2.12119","article-title":"Phase II clinical trial using camrelizumab combined with apatinib and chemotherapy as the first-line treatment of advanced esophageal squamous cell carcinoma","volume":"40","author":"Zhang","year":"2020","journal-title":"Cancer Commun (Lond)"},{"issue":"6230","key":"10.1016\/j.jtcvs.2023.12.030_bib14","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1126\/science.aaa8172","article-title":"The future of immune checkpoint therapy","volume":"348","author":"Sharma","year":"2015","journal-title":"Science"},{"issue":"2","key":"10.1016\/j.jtcvs.2023.12.030_bib15","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1007\/s00262-012-1388-0","article-title":"Chemoimmunotherapy: reengineering tumor immunity","volume":"62","author":"Chen","year":"2013","journal-title":"Cancer Immunol Immunother"},{"issue":"13","key":"10.1016\/j.jtcvs.2023.12.030_bib16","doi-asserted-by":"crossref","first-page":"e498","DOI":"10.1016\/S1470-2045(15)00007-8","article-title":"Radiation and checkpoint blockade immunotherapy: radiosensitisation and potential mechanisms of synergy","volume":"16","author":"Sharabi","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jtcvs.2023.12.030_bib17","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijsu.2022.106767","article-title":"Efficacy and safety of neoadjuvant immunotherapy in surgically resectable esophageal cancer: a systematic review and meta-analysis","volume":"104","author":"Wang","year":"2022","journal-title":"Int J Surg"},{"issue":"3","key":"10.1016\/j.jtcvs.2023.12.030_bib18","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-004291","article-title":"Multicenter, single-arm, phase II trial of camrelizumab and chemotherapy as neoadjuvant treatment for locally advanced esophageal squamous cell carcinoma","volume":"10","author":"Liu","year":"2022","journal-title":"J Immunother Cancer"},{"issue":"1","key":"10.1016\/j.jtcvs.2023.12.030_bib19","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1002\/ijc.33976","article-title":"Neoadjuvant camrelizumab plus chemotherapy for resectable, locally advanced esophageal squamous cell carcinoma (NIC-ESCC2019): a multicenter, phase 2 study","volume":"151","author":"Liu","year":"2022","journal-title":"Int J Cancer"},{"issue":"1","key":"10.1016\/j.jtcvs.2023.12.030_bib20","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-003497","article-title":"Neoadjuvant programmed cell death 1 blockade combined with chemotherapy for resectable esophageal squamous cell carcinoma","volume":"10","author":"Yang","year":"2022","journal-title":"J Immunother Cancer"},{"issue":"1","key":"10.1016\/j.jtcvs.2023.12.030_bib21","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.jtho.2016.10.016","article-title":"Cancer of the esophagus and esophagogastric junction: an eighth edition staging primer","volume":"12","author":"Rice","year":"2017","journal-title":"J Thorac Oncol"},{"issue":"6","key":"10.1016\/j.jtcvs.2023.12.030_bib22","doi-asserted-by":"crossref","first-page":"1632","DOI":"10.1016\/j.jtcvs.2020.09.042","article-title":"Residual tumor characteristics of esophageal squamous cell carcinoma after neoadjuvant chemoradiotherapy","volume":"162","author":"Tang","year":"2021","journal-title":"J Thorac Cardiovasc Surg"},{"key":"10.1016\/j.jtcvs.2023.12.030_bib23","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.849984","article-title":"Neoadjuvant pembrolizumab and chemotherapy in resectable esophageal cancer: an open-label, single-arm study (PEN-ICE)","volume":"13","author":"Duan","year":"2022","journal-title":"Front Immunol"},{"issue":"11","key":"10.1016\/j.jtcvs.2023.12.030_bib24","doi-asserted-by":"crossref","first-page":"2680","DOI":"10.1002\/1097-0142(19940601)73:11<2680::AID-CNCR2820731105>3.0.CO;2-C","article-title":"Pathologic assessment of tumor regression after preoperative chemoradiotherapy of esophageal carcinoma. Clinicopathologic correlations","volume":"73","author":"Mandard","year":"1994","journal-title":"Cancer"},{"issue":"28","key":"10.1016\/j.jtcvs.2023.12.030_bib25","doi-asserted-by":"crossref","first-page":"3661","DOI":"10.1002\/sim.6607","article-title":"Moving towards best practice when using inverse probability of treatment weighting (IPTW) using the propensity score to estimate causal treatment effects in observational studies","volume":"34","author":"Austin","year":"2015","journal-title":"Stat Med"},{"issue":"6","key":"10.1016\/j.jtcvs.2023.12.030_bib26","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1093\/aje\/kwac014","article-title":"On variance of the treatment effect in the treated when estimated by inverse probability weighting","volume":"191","author":"Reifeis","year":"2022","journal-title":"Am J Epidemiol"},{"issue":"27","key":"10.1016\/j.jtcvs.2023.12.030_bib27","doi-asserted-by":"crossref","first-page":"2796","DOI":"10.1200\/JCO.2018.79.1483","article-title":"Neoadjuvant chemoradiotherapy followed by surgery versus surgery alone for locally advanced squamous cell carcinoma of the esophagus (NEOCRTEC5010): a phase III multicenter, randomized, open-label clinical trial","volume":"36","author":"Yang","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtcvs.2023.12.030_bib28","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.1052542","article-title":"Pathologic responses and surgical outcomes after neoadjuvant immunochemotherapy versus neoadjuvant chemoradiotherapy in patients with locally advanced esophageal squamous cell carcinoma","volume":"13","author":"Xu","year":"2022","journal-title":"Front Immunol"},{"issue":"2","key":"10.1016\/j.jtcvs.2023.12.030_bib29","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.annonc.2022.10.508","article-title":"Neoadjuvant chemoradiotherapy versus neoadjuvant chemotherapy followed by minimally invasive esophagectomy for locally advanced esophageal squamous cell carcinoma: a prospective multi-center randomized clinical trial","volume":"34","author":"Tang","year":"2023","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jtcvs.2023.12.030_bib30","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.970534","article-title":"Comparison of neoadjuvant immunotherapy plus chemotherapy versus chemotherapy alone for patients with locally advanced esophageal squamous cell carcinoma: a propensity score matching","volume":"13","author":"Jing","year":"2022","journal-title":"Front Immunol"},{"issue":"7798","key":"10.1016\/j.jtcvs.2023.12.030_bib31","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1038\/s41586-020-2054-x","article-title":"Epigenetic therapy inhibits metastases by disrupting premetastatic niches","volume":"579","author":"Lu","year":"2020","journal-title":"Nature"}],"container-title":["The Journal of Thoracic and Cardiovascular Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022522324000084?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022522324000084?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T02:15:03Z","timestamp":1785550503000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022522324000084"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8]]},"references-count":31,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,8]]}},"alternative-id":["S0022522324000084"],"URL":"https:\/\/doi.org\/10.1016\/j.jtcvs.2023.12.030","relation":{},"ISSN":["0022-5223"],"issn-type":[{"value":"0022-5223","type":"print"}],"subject":[],"published":{"date-parts":[[2024,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Neoadjuvant chemotherapy combined with immunotherapy versus neoadjuvant chemoradiotherapy in patients with locally advanced esophageal squamous cell carcinoma","name":"articletitle","label":"Article Title"},{"value":"The Journal of Thoracic and Cardiovascular Surgery","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtcvs.2023.12.030","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 by The American Association for Thoracic Surgery","name":"copyright","label":"Copyright"}]}}